Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis
Thomas B. Casale(University of South Florida), Adam L. Asare(Quantum Leap Healthcare Collaborative), Zuhair K. Ballas(University of Iowa), Joel N. Kline(University of Iowa Health Care), William W. Busse(University of Wisconsin–Madison), Mark Moss(University of Wisconsin–Madison), Masoud Mokhtarani, Kirk Bateman(University of Iowa), Vicki Seyfert‐Margolis(University of Washington)
Cited by 359
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k